Thematische Bibliographien / Cardioprotective / Bücher
Um die anderen Arten von Veröffentlichungen zu diesem Thema anzuzeigen, folgen Sie diesem Link: Cardioprotective.

Bücher zum Thema „Cardioprotective“

Autor: Grafiati
Veröffentlicht am 18. Mai 2024

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit Top-46 Bücher für die Forschung zum Thema "Cardioprotective" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Sehen Sie die Bücher für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.

1

Kendall, Martin J. Preventing coronary artery disease: Cardioprotective therapeutics in practice. 2. Aufl. London: Martin Dunitz, 1998.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

M, Beale C., Hrsg. The cardioprotective role of HRT: A clinical update. New York: Parthenon Pub. Group, 1996.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

(Germany)), Freiburg Focus on Biomeasurement (9th 1995 Freiburg im Breisgau. Pharmacological evaluation of cardioprotective substances: Experimental induction and indicators of myocardial injury and myocardial protection. Buchenbach, Germany: Gesellschaft für Erfahrungstransfer in der Biomesstechnik e.V., 1996.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Cardioprotection. Oxford: Oxford University Press, 2009.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

International Symposium, Calcium Antagonists in Cardiovascular Care (1991 : Basle, Switzerland), Hrsg. Verapamil-- a cardioprotective strategy: Highlights from a satellite symposium to the International Symposium, Calcium Antagonists in Cardiovascular Care, Basle, Switzerland, Feb. 13, 1991. New York, NY: Raven Health Care Communications, 1991.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Minatoguchi, Shinya. Cardioprotection Against Acute Myocardial Infarction. Singapore: Springer Singapore, 2019. http://dx.doi.org/10.1007/978-981-15-0167-8.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Baxter, G. F., und D. M. Yellon, Hrsg. Delayed Preconditioning and Adaptive Cardioprotection. Dordrecht: Springer Netherlands, 1998. http://dx.doi.org/10.1007/978-94-011-5312-6.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

F, Baxter G., und Yellon Derek M, Hrsg. Delayed preconditioning and adaptive cardioprotection. Dordrecht: Kluwer Academic Publishers, 1998.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Mentzer, Robert M., Masafumi Kitakaze, James M. Downey und Masatsugu Hori, Hrsg. Adenosine, Cardioprotection and Its Clinical Application. Boston, MA: Springer US, 1997. http://dx.doi.org/10.1007/978-1-4419-8736-5.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

M, Mentzer Robert, Hrsg. Adenosine, cardioprotection, and its clinical application. Boston: Kluwer Academic Publishers, 1997.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
11

Przyklenk, Karin, Robert A. Kloner und Derek M. Yellon, Hrsg. Ischemic Preconditioning: The Concept of Endogenous Cardioprotection. Boston, MA: Springer US, 1994. http://dx.doi.org/10.1007/978-1-4615-2602-5.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
12

1956-, Przyklenk Karin, Kloner Robert A und Yellon Derek M, Hrsg. Ischemic preconditioning: The concept of endogenous cardioprotection. Boston: Kluwer Academic Publishers, 1993.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
13

Sutter, Johan De, Miguel Mendes und Oscar H. Franco. Cardioprotective drugs. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199656653.003.0019.

Der volle Inhalt der Quelle
Annotation:
Cardioprotective drugs are important in the treatment of patients at risk for or with documented cardiovascular disease. Beta-blockers are indicated after acute coronary syndromes, stable coronary artery disease, heart failure, and arrhythmias. Angiotensin-converting enzyme inhibitors (ACEi) are important in congestive heart failure, stable angina, post-acute myocardial infarction, and secondary prevention after any event or revascularization. Angiotensin receptor blockers are mainly alternative drugs for the same indications in case of intolerance to ACEi. Calcium channel blockers are first line medication for patients with isolated systolic hypertension, black people, and during pregnancy, in the presence of intermittent claudication, asymptomatic atherosclerosis, or metabolic syndrome. A polypill is a combination pill in which multiple medications effective in the prevention of cardiovascular disease (for example statins, antihypertensives, and aspirin) are put together in a single pill.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
14

Sutter, Johan De, Miguel Mendes und Oscar H. Franco. Cardioprotective drugs. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199656653.003.0019_update_001.

Der volle Inhalt der Quelle
Annotation:
Cardioprotective drugs are important in the treatment of patients at risk for or with documented cardiovascular disease. Beta-blockers are indicated after acute coronary syndromes, stable coronary artery disease, heart failure, and arrhythmias. Angiotensin-converting enzyme inhibitors (ACEi) are important in congestive heart failure, stable angina, post-acute myocardial infarction, and secondary prevention after any event or revascularization. Angiotensin receptor blockers are mainly alternative drugs for the same indications in case of intolerance to ACEi. Calcium channel blockers are first line medication for patients with isolated systolic hypertension, black people, and during pregnancy, in the presence of intermittent claudication, asymptomatic atherosclerosis, or metabolic syndrome. A polypill is a combination pill in which multiple medications effective in the prevention of cardiovascular disease (for example statins, antihypertensives, and aspirin) are put together in a single pill.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
15

Brahmachari, Goutam. Cardioprotective Natural Products. WORLD SCIENTIFIC, 2017. http://dx.doi.org/10.1142/10740.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
16

Hausenloy, Derek, und Derek Yellon, Hrsg. Novel Cardioprotective Strategies. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780199544769.003.0011.

Der volle Inhalt der Quelle
Annotation:
• Despite optimal therapy, the mortality and morbidity of coronary heart disease remains significant. Hence, novel treatment strategies of cardioprotection are required to improve clinical outcomes in these patients• Experimental studies have provided a plethora of therapeutic strategies for reducing myocardial injury, but the translation of these findings into the clinical setting has been largely disappointing. Many of these unsuccessful clinical studies have relied upon individually targeting established mediators of lethal reperfusion injury such as oxidative stress, inflammation, calcium overload and so forth• Clearly, novel targets for cardioprotection as well as a multi-targeted approach to cardioprotection directed against the multiple causes of lethal reperfusion injury are required to effect benefits in clinical outcomes• In this regard, the introduction of ischaemic postconditioning, a novel treatment strategy, in which following primary PCI the process of myocardial reperfusion is interrupted by several coronary re-occlusions, has been reported to reduce myocardial myocardial injury in AMI patients• Furthermore, experimental studies have identified the Reperfusion Injury Salvage Kinase (RISK) pathway and the mitochondrial permeability transition pore (mPTP) as novel targets for cardioprotection, which are currently been examined in the clinical setting.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
17

Hausenloy, Derek, und Derek Yellon, Hrsg. An Introduction to Cardioprotection. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780199544769.003.0001.

Der volle Inhalt der Quelle
Annotation:
• In its broadest sense, the term ‘cardioprotection’ encompasses ‘all mechanisms and means that contribute to the preservation of the heart by reducing or even preventing myocardial damage’• However, for the purposes of this book, the term ‘cardioprotection’ will refer to the endogenous mechanisms and therapeutic strategies that reduce or prevent myocardial damage induced by acute ischaemia-reperfusion injury• In this context, cardioprotection begins with the primary prevention of coronary heart disease and includes the reduction of myocardial injury sustained during coronary artery bypass graft surgery, and an acute myocardial infarction, conditions with considerable morbidity and mortality• An understanding of the pathophysiology of acute myocardial ischaemia-reperfusion injury is essential when designing new cardioprotective strategies• Several methods exist for both quantifying myocardial damage induced by acute ischaemia-reperfusion injury and for assessing myocardial salvage following the application of cardioprotective strategies• Importantly, novel cardioprotective strategies must be capable of preventing and reducing myocardial damage over and above that provided by current optimal therapy.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
18

Brahmachari, Goutam. Cardioprotective Natural Products: Promises and Hopes. World Scientific Publishing Co Pte Ltd, 2017.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
19

Horton, Richard C., und Martin J. Kendall. Preventing Coronary Artery Disease: Cardioprotective Therapeutics in the 1990s. Scovill-Paterson, 1994.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
20

Publishers, Collins. Cardioprotective Role of Hrt a Clinical Update Portugeuse E. Taylor & Francis Group, 1997.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
21

Pepper, John. Cardioprotection During Cardiac Surgery. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780199544769.003.0007.

Der volle Inhalt der Quelle
Annotation:
• Overall early mortality for cardiac surgery is low at 2–3% but in high risk patients it can be high as 10–15%• The demography of cardiac surgical patients is changing to older and sicker patients• Myocardial ischaemia-reperfusion injury and the systemic inflammatory response are closely related• Several pharmacological agents that have been demon-strated to confer cardioprotection in the experimental setting have been applied to the clinical setting of cardiac surgery. However, the transfer of these findings from the bench to the bedside has been largely disappointing• Potential cardioprotective strategies include pharma-cological agents such as adenosine, and mechanical interventional strategies such as acute normovolaemic haemodilution and remote ischaemic preconditioning.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
22

Downey, James, und Michael Cohen. Endogenous Mechanisms of Cardioprotection. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780199544769.003.0008.

Der volle Inhalt der Quelle
Annotation:
• Ischaemic preconditioning is the most powerful endogenous mechanism for limiting myocardial infarct size in the experimental setting. Its clinical application is limited to scenarios in which the index episode of ischaemia and reperfusion can be anticipated such as in the setting of cardiac surgery• Ischaemic postconditioning represents an endogenous cardioprotective strategy which is applied at the onset of myocardial reperfusion, thereby allowing its use as an adjunct to reperfusion in patients presenting with an acute myocardial infarction• Both ischaemic preconditioning and postconditioning recruit a common signal transduction pathway at the time of myocardial reperfusion, which can be targeted by pharmacological agents administered as adjuncts to reperfusion.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
23

Momin, Firoz, Nilofar Naikwade und Tabassum Shikalgar. Cardioprotective Effect of Combination of Enalapril and Fenofibrate: A Hemodynamic, Biochemical and Histopathological Study. LAP Lambert Academic Publishing, 2011.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
24

Dallongeville, Jean, Deborah Lycett und Monique Verschuren. Nutrition. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199656653.003.0011.

Der volle Inhalt der Quelle
Annotation:
Different aspects of the human diet are causally related to atherosclerosis and its clinical consequences; therefore a balanced and healthy diet is the cornerstone of the prevention of cardiovascular disease. In this chapter an overview is given of the medical evidence supporting the importance of nutrition in prevention of cardiovascular disease; practical ways to cultivate cardioprotective dietary habits are summarized not only in terms of macro- and micronutrients but also in relation to foods, functional foods. and portfolio diets.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
25

Hausenloy, Derek, und Derek Yellon, Hrsg. Cardioprotection. Oxford University Press, 2009. http://dx.doi.org/10.1093/med/9780199544769.001.0001.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
26

Hausenloy, Derek, und Derek Yellon. Cardioprotection. Oxford University Press, 2014.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
27

Hausenloy, Derek, und Derek Yellon. Cardioprotection. Oxford University Press, Incorporated, 2009.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
28

Tiezzi, Antonio, Elisa Ovidi und Tomasz M. Karpiński, Hrsg. New Findings from Natural Substances. BENTHAM SCIENCE PUBLISHERS, 2022. http://dx.doi.org/10.2174/97898150514211220101.

Der volle Inhalt der Quelle
Annotation:
New Findings from Natural Substances present the state-of-the-art and future prospects for the application of biomolecules in the pharmaceutical, agricultural, food and industrial sectors. The book presents eight reviews contributed by more than twenty experts on interesting natural substances, and plant sources, that serve as sources of natural remedies for a variety of ailments. The reviews in the book cover the use of herbs like Heliotropium and Astragalus. Additional health benefits of extracts from essential oils, Caenorhabditis elegans, and olive oil, as well as the medicinal use of rosmarinic acid and hydrolates. The contributions highlight a range of pharmacological agents from natural sources that have anti-cancer, anti-inflammatory, cardioprotective and neuroprotective effects. The contents are presented in a simple and organized style. The book will broaden the knowledge about biological products for a variety of readers - generalists, students and researchers, alike.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
29

Kendall, Marion D. Beta Blockade and Cardioprotection. Science Press, 1991.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
30

Penna, Claudia, Nina Kaludercic, Valentina Mercurio und Nazareno Paolocci, Hrsg. Cardioprotection, Sex and Gender Differences. Frontiers Media SA, 2022. http://dx.doi.org/10.3389/978-2-83250-207-5.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
31

Minatoguchi, Shinya. Cardioprotection Against Acute Myocardial Infarction. Springer Singapore Pte. Limited, 2021.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
32

Yellon, Derek M., und G. F. Baxter. Delayed Preconditioning and Adaptive Cardioprotection. Springer, 2012.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
33

Minatoguchi, Shinya. Cardioprotection Against Acute Myocardial Infarction. Springer, 2020.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
34

Yellon, Derek M., und G. F. Baxter. Delayed Preconditioning and Adaptive Cardioprotection. Springer London, Limited, 2012.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
35

Kitakaze, Masafumi, James M. Downey, Masatsugu Hori und Robert M. Mentzer Jr. Adenosine, Cardioprotection and Its Clinical Application. Springer London, Limited, 2012.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
36

Jr, Robert M. Mentzer. "Adenosine, Cardioprotection and Its Clinical Application". Springer, 2012.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
37

Yellon, Derek M., Robert A. Kloner und Karin Przyklenk. Ischemic Preconditioning: The Concept of Endogenous Cardioprotection. Springer London, Limited, 2012.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
38

Ischemic Preconditioning: The Concept of Endogenous Cardioprotection. Springer My Copy UK, 1993.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
39

Yellon, Derek M., Robert A. Kloner und Karin Przyklenk. Ischemic Preconditioning: The Concept of Endogenous Cardioprotection. Springer London, Limited, 2012.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
40

Cell Survival Programs And Ischemiareperfusion Hormesis Preconditioning And Cardioprotection. Biota Publishing, 2013.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
41

Korthuis, Ronald, Maike Krenz, Theodore Kalogeris und Christopher Baines. Cell Survival Programs and Ischemia/Reperfusion: Hormesis, Preconditioning, and Cardioprotection. Morgan & Claypool Life Science Publishers, 2013.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
42

Pathophysiology of Ischemia Reperfusion Injury and Use of Fingolimod in Cardioprotection. Elsevier, 2019. http://dx.doi.org/10.1016/c2018-0-02692-4.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
43

Ahmed, Naseer, und Soban Sadiq. Pathophysiology of Ischemia Reperfusion Injury and Use of Fingolimod in Cardioprotection. Elsevier Science & Technology, 2019.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
44

Ahmed, Naseer. Pathophysiology of Ischemia Reperfusion Injury and Use of Fingolimod in Cardioprotection. Elsevier Science & Technology Books, 2019.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
45

(Editor), Karin Przyklenk, Robert A. Kloner (Editor) und D. M. Yellon (Editor), Hrsg. Ischemic `Preconditioning': The Concept of Endogenous Cardioprotection (Developments in Cardiovascular Medicine). Springer, 1993.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
46

Boloorchi, Azadeh. The role of protein kinase C-epsilon (PKCepsilon) in ischemic preconditioning cardioprotection induced by enhancement of cell volume regulation. 2006.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Die Auswahlen zum Thema "Cardioprotective" für andere Quellenarten können Sie auch interessieren:
Zeitschriftenartikel Dissertationen
Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!

Zur Bibliographie